Slide 1: Q1 2026 Results
Q1 2026 Results Conference call and webcast for investors and analysts 29 April 2026
Slide 2: Cautionary statements regarding forward-looking statements
Cautionary statements regarding forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certai
Slide 3: Conference call agenda
Q1 2026 Results Conference call agenda CEO Opening Remarks Pascal Soriot Chief Executive Officer Financial Results Aradhana Sarin Chief Financial Officer Oncology Haematology Dave Fredrickson Susan Galbraith EVP, Oncology Haematology Business EVP, Oncology Haematology R&D BioPharmaceuticals Ruud Dob
Slide 4: CEO Opening Remarks
CEO Opening Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER 4
Slide 5: Strong commercial performance in Q1 2026 with continued excellent pipeline delivery
Strong commercial performance in Q1 2026 with continued excellent pipeline delivery +8% Total Revenue Sustained commercial momentum +12% Core Operating Profit +5% Core EPS1 First Phase III tozorakimab efzimfotase alfa data for NMEs COPD HPP High-value readouts across 4 Phase III programmes2 Indicati
Slide 6: Growth driven by diverse global presence and sources of business
Growth driven by diverse global presence and sources of business Q1 2026 | % Product Revenue by therapy area +16% -2% ID: 182 -22% Oncology CVRM R&I ID Other Rare Disease Strength across R&I: 2,318 +7% 45% 21% 15% 1% 2% 16% therapy areas +15% Q1 2026 | +8% Product Revenue ($m)1 CVRM: -7% 6,797 3,241
Slide 7: Continuing our successful pipeline delivery across TAs
Continuing our successful pipeline delivery across TAs Key Phase III trial readouts in Q1 2026 Imfinzi + Imjudo tozorakimab efzimfotase alfa Ultomiris OBERON/ HICKORY/ HICKORY/ EMERALD-3 TITANIA/ CHESTNUT/ CHESTNUT/ I CAN MIRANDA MULBERRY MULBERRY Locoregional HCC COPD HPP IgAN Multiple high-value r
Slide 8: Financial Results
Financial Results Aradhana Sarin CHIEF FINANCIAL OFFICER 8
Slide 9: Q1 2026 – Reported profit and loss
Q1 2026 – Reported profit and loss Q1 2026 CER change % Total $m % Revenue - Product Sales 14,386 7 94 - Alliance Revenue 825 26 5 Product Revenue 15,211 8 99 - Collaboration Revenue 77 - 1 Total Revenue 15,288 8 100 Gross Margin 82% +1pp - R&D expense (3,492) 7 23 - SG&A expense (4,920) 6 32 Total
Slide 10: Q1 2026 – Core profit and loss
Q1 2026 – Core profit and loss Q1 2026 CER change % Total $m % Revenue - Product Sales 14,386 7 94 - Alliance Revenue 825 26 5 Product Revenue 15,211 8 99 - Collaboration Revenue 77 - 1 Total Revenue 15,288 8 100 Gross Margin 83% +1pp - R&D expense (3,461) 8 23 - SG&A expense (3,859) 7 25 Total oper
Slide 11: FY 2026 guidance reiterated
FY 2026 guidance reiterated Capital allocation priorities remain unchanged Net debt/EBITDA 1.3x FY 2026 Guidance (CER) $bn Total Anticipated to increase by a 0.9 mid-to-high single-digit 3.4 1.1 3.3 Revenue percentage 0.6 Anticipated to increase by a 23.4 25.9 Core EPS low double-digit percentage Ne
Slide 12: Oncology
Oncology Dave Fredrickson ONCOLOGY HAEMATOLOGY BUSINESS Susan Galbraith ONCOLOGY HAEMATOLOGY R&D 12
Slide 13: Oncology – Q1 2026
Oncology – Q1 2026 Total Revenue $6.8bn driven by strong global demand across key medicines Oncology Q1 2026: key dynamics Q1 2026 $6.8bn, +16% 7,500 • Tagrisso +5%, robust demand across indications, continued 1L combination growth 7,000 6,500 • Imfinzi +30%, Imjudo (7%), strong demand across region
Slide 14: Oncology – advancing pipeline at ASCO 2026
Oncology – advancing pipeline at ASCO 2026 Positive Phase III for Imfinzi + Imjudo in HCC, encouraging early data across portfolio Imfinzi + Imjudo | Moving earlier into locoregional Further evidence for key transformative HCC with EMERALD-3 technologies at ASCO Expanding leadership position in grow
Slide 15: BioPharmaceuticals
BioPharmaceuticals Ruud Dobber BIOPHARMACEUTICALS BUSINESS Sharon Barr BIOPHARMACEUTICALS R&D 15
Slide 16: BioPharmaceuticals – Q1 2026
BioPharmaceuticals – Q1 2026 Total Revenue $5.8bn, CVRM LoEs largely offset by growth in R&I and new products R&I CVRM Q1 2026: key dynamics Q1 2026 $2.3bn, +7% Q1 2026 $3.3bn, -6% • Fasenra +11%, sustained IL-5 leadership 2,500 3,500 in asthma, EGPA launch • Breztri +13%, fastest growing medicine i
Slide 17: BioPharmaceuticals – expanding leadership in COPD
BioPharmaceuticals – expanding leadership in COPD Tozorakimab first biologic effective in all-comers COPD population in 3 pivotal trials tozorakimab | Potential first-in-class IL-33 biologic in COPD Remaining high unmet need in COPD tozorakimab uniquely inhibits signaling of reduced and oxidised for
Slide 18: Rare Disease
Rare Disease Marc Dunoyer CHIEF EXECUTIVE OFFICER, ALEXION 18
Slide 19: Rare Disease – Q1 2026
Rare Disease – Q1 2026 Total Revenue $2.4bn driven by continued patient demand across the portfolio Rare Disease Q1 2026: key dynamics Q1 2026 $2.4bn, +15% 2,500 C5 Franchise • Ultomiris +18%, demand growth across indications, including within the competitive gMG and PNH markets 2,000 • Soliris (14%
Slide 20: Rare Disease – extending our leadership
Rare Disease – extending our leadership Two positive Phase III programmes in rare metabolic and renal diseases efzimfotase alfa | Positive results from global Ultomiris | I CAN interim analysis showed Phase III clinical programme in HPP patients improvement in UPCR in IgAN patients Addresses broad d
Slide 21: CEO Closing Remarks
CEO Closing Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER 21
Slide 22: Phase III pipeline momentum continues across 2026
Phase III pipeline momentum continues across 2026 H1 2026 H2 2026 EMERALD-3 | Imfinzi + Imjudo AVANZAR | Datroway + Imfinzi CROSSING | Tezspire locoregional hepatocellular carcinoma 1L NSQ/NSQ TROP2+ NSCLC eosinophilic esophagitis VOLGA | Imfinzi ± Imjudo TROPION-Lung15 | Datroway ± Tagrisso 2L CARD
Slide 23: Strong R&D execution underpins milestone-rich 2026
Strong R&D execution underpins milestone-rich 2026 Key upcoming 2026 data presentations and regulatory decisions Key data presentations First regulatory decisions Subsequent major market approvals ASCO | Multiple datasets DESTINY-Breast11 | Enhertu May/Jun TROPION-Breast02 | Datroway H1 H1 PhIII EME
Slide 24: Increasing confidence in Ambition 2030 and continued growth beyond
Increasing confidence in Ambition 2030 and continued growth beyond Continued commercial Advancing towards $80bn Investment in growth momentum in 2026 2030 Total Revenue ambition1 beyond 2030 Strong global demand Significant pipeline progress Strategic focus to fuel across medicines increases confide
Slide 25: Q&A Session
Q&A Session Pascal Soriot Aradhana Sarin CHIEF EXECUTIVE OFFICER CHIEF FINANCIAL OFFICER Marc Dunoyer Susan Galbraith CHIEF EXECUTIVE EVP, ONCOLOGY HAEMATOLOGY R&D OFFICER, ALEXION Dave Fredrickson Sharon Barr EVP, ONCOLOGY EVP, BIOPHARMACEUTICALS R&D HAEMATOLOGY BUSINESS Ruud Dobber Iskra Reic EVP,
Slide 26: Appendix
Appendix
Slide 27: AstraZeneca P&L reference table
APPEN DI X | P&L definitions AstraZeneca P&L reference table P&L line-item definitions P&L line-item definition Product Sales • Recognises sales from territories where Group has lead commercialisation • Recognises supply of Beyfortus to Sanofi Alliance Revenue • Alliance Revenue comprises income ari
Slide 28: Non-risk adjusted peak-year revenue guidance
APPEN DI X | PYR Revenue Guidance Non-risk adjusted peak-year revenue guidance Approved medicines Phase III pipeline Earlier pipeline camizestrant (next generation oral SERD) weight management (oGLP-1/FDCs) rilvegostomig (PD-1/TIGIT bispecific mAb) saruparib (PARP1 inhibitor) $5bn+ surovatamig (CD19
Slide 29: AstraZeneca in non-small cell lung cancer
APPEN DI X | Oncology tumour maps AstraZeneca in non-small cell lung cancer Resectable Unresectable Metastatic Stg. I Stg. II-III Stg. I-II Stg. III 1L 2L 3L+ Est. epi (G7, 2025) ~150K ~70K ~50K ~100K ~310K ~190K ~70K CRT → Imfinzi Imfinzi + Imjudo + CTx POSEIDON PACIFIC Datroway + IO ± platinum TL0
Slide 30: AstraZeneca in breast cancer
APPEN DI X | Oncology tumour maps AstraZeneca in breast cancer Early Metastatic Neoadjuvant Adjuvant 1st line 2nd line 3rd line 4th line + Est. epi (G7, 2025) 540k 135k 100k 75k 60k HER2-positive Enhertu → THP NST→ residual disease → Enhertu Enhertu ± pertuzumab Enhertu Enhertu 15-20% DESTINY-Breast
Slide 31: AstraZeneca in gastric cancer
APPEN DI X | Oncology tumour maps AstraZeneca in gastric cancer Early Advanced/Metastatic Stage II/III 1st line 2nd line 3rd line Est. epi (G7, 2025) 50k 90k 60k 30k Enhertu + rilvegostomig + FP HER2-positive ARTEMIDE-Gastric01 Enhertu Enhertu 20% DESTINY-Gastric02, 04 DESTINY-Gastric01 Enhertu + pe
Slide 32: Oncology
APPEN DI X | Product Revenue Performance Oncology Tagrisso Lynparza 5% growth at CER to $1,833m in Q1 2026 2% growth at CER to $781m in Q1 2026 1,000 2,000 900 1,800 800 1,600 700 1,400 Product Revenue ($m) Product Revenue ($m) 600 1,200 500 1,000 800 400 600 300 400 200 200 100 0 0 Q1 Q2 Q3 Q4 Q1 Q
Slide 33: Oncology
APPEN DI X | Product Revenue Performance Oncology Imfinzi Imjudo 30% growth at CER to $1,694m in Q1 2026 7% decrease at CER to $77m in Q1 2026 2,000 100 1,800 90 1,600 80 1,400 70 Product Revenue ($m) Product Revenue ($m) 1,200 60 1,000 50 800 40 600 30 400 20 200 10 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q
Slide 34: Oncology
APPEN DI X | Product Revenue Performance Oncology Calquence Enhertu 17% growth at CER to $923m in Q1 2026 34% growth at CER to $831m in Q1 2026 1,200 900 800 1,000 700 800 600 Product Revenue ($m) Product Revenue ($m) 500 600 400 400 300 200 200 100 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q1 Q2 Q
Slide 35: BioPharmaceuticals: Respiratory & Immunology
APPEN DI X | Product Revenue Performance BioPharmaceuticals: Respiratory & Immunology Fasenra Tezspire Saphnelo 11% growth at CER to $483m in Q1 2026 34% growth at CER to $303m in Q1 2026 24% growth at CER to $171m in Q1 2026 600 400 250 350 500 200 300 400 Product Revenue ($m) Product Revenue ($m)
Slide 36: BioPharmaceuticals: Respiratory & Immunology
APPEN DI X | Product Revenue Performance BioPharmaceuticals: Respiratory & Immunology Breztri Symbicort 13% growth at CER to $353m in Q1 2026 1% decrease at CER to $747m in Q1 2026 400 900 350 800 700 300 600 Product Revenue ($m) Product Revenue ($m) 250 500 200 400 150 300 100 200 50 100 0 0 Q1 Q2
Slide 37: BioPharmaceuticals: Cardiovascular, Renal & Metabolism
APPEN DI X | Product Revenue Performance BioPharmaceuticals: Cardiovascular, Renal & Metabolism Farxiga Brilinta Lokelma 2% decrease at CER to $2,193m in Q1 2026 67% decrease at CER to $105m in Q1 2026 26% growth at CER to $199m in Q1 2026 2,500 400 250 350 2,000 200 300 Product Revenue ($m) Product
Slide 38: Rare Disease
APPEN DI X | Product Revenue Performance Rare Disease Ultomiris Strensiq Koselugo 18% growth at CER to $1,270m in Q1 2026 43% growth at CER to $517m in Q1 2026 15% growth at CER to $170m in Q1 2026 1,400 600 250 1,200 500 200 1,000 400 Product Revenue ($m) Product Revenue ($m) Product Revenue ($m) 1
Slide 39: Glossary
APPEN DI X | Glossary Glossary 1L, 2L, 3L first-, second-, third-line Eta endothelin A NST neoadjuvant systemic therapy ADA American Diabetes Association EU Europe OS overall survival ADC antibody-drug conjugate FDC fixed-dose combination PALB2m partner and localizer of BRCA2 adv. advanced FLOT fluo
Slide 40: Confidentiality Notice
Confidentiality Notice This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or dis